Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deforolimus randomized discontinuation phase II trial in KRAS-mutant NSCLC
2008-005942-22Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2008
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ridaforolimus in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Started Dec 2008; status: terminated.
02
Drugs
ridaforolimus
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-005942-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005942-22.